Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Find the Insider facts of Compelling Systems administration: Building Associations for Progress - 2Russian military plane crashes in annexed Crimea, killing 29 people on board
- 3Ads promising cosmetic surgery patients a ‘dream body’ with minimal risk get little scrutiny
- 4New method spots signs of Earth's primordial life in ancient rocks
- 5I decided to become a single mother by choice. I wasn't ready to stop dating.
- 20-year-old who threatened German train attack remanded in custody
- Mom finds out she has cancer after noticing something was off while breastfeeding
- Winter virus season so far is not too bad, but doctors worry about suffering to come
- 4 Famous Gaming PCs of 2024: Execution, Versatility, and Advancement
- Family Matters: Tips and Guidance for Effective Nurturing and Everyday Life
- 10 Demonstrated Tips to Dominate Video Altering on Your Cell phone in 2023
- Over 1,800 killed since junta seized power in Burkina Faso, rights group says
- Parents speak out as 4-year-old fights button battery injury in intensive care unit
- Building a Maintainable Closet: Individual Excursions in Moral Style
